Tyrosine kinase c-Abl
Activation of tyrosine kinase c Abl contributes to α synuclein–induced neurodegeneration
... at tyrosine 39 plays any role in ...with kinase-active c-Abl (c-Abl- KA) or the KD version, or myc-tagged WT-Y39F α-synuclein along with c-Abl-KA, was overexpressed ...
20
The c Abl tyrosine kinase phosphorylates the Fe65 adaptor protein to stimulate Fe65/amyloid precursor protein nuclear signaling
... to c-Abl and c-Abl ⌬ XB through its WW domain, and Fe65 and c-Abl are both present in the ...of c-Abl and c-Abl⌬XB in Fe65 immunoprecipitates from ...
8
Distinct Transforming Activity of ABL Family Tyrosine Kinase Oncogenes Is Induced by Their C Terminal Domain*
... the kinase domain or C-terminus of ARG with the corresponding domain in ABL were generated, and each mutant was expressed in Ba/F3 ...the ABL kinase domain was similar to TEL/ARG in ...
11
A chimeric receptor/oncogene that can be regulated by a ligand in vitro and in vivo
... activated tyrosine ki- nase that causes human chronic myelogenous ...of ABL, thereby activating ABL tyrosine kinase ...if ABL was dimerized through other mechanisms, activation ...
9
Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia
... protein tyrosine kinases ...protein kinase inhibitors that can block or modulate diseases with abnormalities in these signaling pathways is considered a promising approach for drug ...protein kinase ...
6
Imatinib mesylate inhibits the profibrogenic activity of TGF β and prevents bleomycin mediated lung fibrosis
... the c-Abelson (c-Abl) proto-oncogene has a potential role in regulating cytokine-mediated fibrosis, since it functions in cell cycle regulation and cytoskeletal remodel- ing and is a downstream ...
10
c Abl regulates YAPY357 phosphorylation to activate endothelial atherogenic responses to disturbed flow
... adhesion kinase (FAK) and c-Src, mediate the signal transduction of integrins ...(22). c-Abl has been shown to be colocalized with inte- grin α5 and activated in cells subjected to fibronectin ...
14
Characteristics and mutation analysis of Ph-positive leukemia patients with T315I mutation receiving tyrosine kinase inhibitors
... the ABL kinase amino acid by interfering directly with the binding of the TKI to the ABL kinase or by inhibiting inactivation of ABL kinase, thereby inter- fering with the ...
8
Role and regulation of Abelson tyrosine kinase in Crk-associated substrate/profilin-1 interaction and airway smooth muscle contraction
... and c-Abl -lox mice were previously described [27]. c-Abl -lox mice were a gift of ...Laboratory. c-Abl -lox mice (genetic background, 129/Svj) were crossed with SM22 cre mice on ...
12
Chapman, Rob (2003): A Functional Analysis of the RNA Polymerase II Large Subunit C-Terminal Domain. Dissertation, LMU München: Fakultät für Biologie
... the Abl-Pol II interaction may be expected to affect the transcription of some ...Indeed, c-Abl has been shown to influence transcriptional elongation at the HIV-1 promoter (Baskaran et ...The ...
133
Bosutinib: a SRC–ABL tyrosine kinase inhibitor for treatment of chronic myeloid leukemia
... Following a single oral dose of BOS 500 mg with food, median time-to-peak concentration (T max ) was 4–6 hours. BOS exhibited linear kinetics with dose proportional increases in area under the curve (AUC) and a maximum ...
6
The Effect of Bcr-Abl Protein Tyrosine Kinase on Maturation and Proliferation of Primitive Haematopoietic Cells
... elevated kinase activity has yet to be clearly defined. Since the Bcr-Abl translocation is known to occur in the stem cell compartment of CML patients, it is the expression of Bcr-Abl in the context ...
11
Refining targeted therapies in chronic myeloid leukemia: development and application of nilotinib, a step beyond imatinib
... received previous therapy other than imatinib and 81% of all patients were imatinib resistant, with 49% previously treated with at least 800 mg. Among the 119 patients an overall HR rate of 47% was observed in a median ...
10
IGF-IR determines the fates of BCR/ABL leukemia
... Figure 1 IGF-2 receptor expression in fetal liver cells. (A) Production and secretion of IGF2-hFc in transfected 293T cells. The upper panel shows a schematic of the plasmid expressing the human prepro-IGF-2 protein ...
9
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
... of tyrosine kinase inhibitors (TKIs) revolutionized therapy for CML, such that durable response, increased overall survival, and increased progression-free survival of patients in chronic phase CML is now ...
9
Masked inv dup(22)(q11.23), tetrasomy 8 and trisomy 19 in a blast crisis-chronic myeloid leukemia after interrupted Imatinib-treatment
... Clinical resistance by BCR-ABL1 amplification mech- anism is uncommon, but not a really rare event in CML resistance to treatment. Amplification of the Ph chromo- some on conventional karyotyping may present as double ...
5
The minimum transforming region of v-abl is the segment encoding protein-tyrosine kinase.
... Insertions of four amino acids, generated by putting synthetic DNA linkers into various restriction enzyme cleavage sites, abolished transforming activity, indicating that much of the in[r] ...
9
Role of C-Kit Receptor Tyrosine Kinase on INS-1 Cell VEGF-A Expression in Vitro
... Several daughter cell lines were derived from the INS-1 and INS-2 cell lines, including INS-1 832, INS-1 832/2, and INS-1 832/13. The INS-1 832 and INS-1 832/2 cell lines exhibit higher insulin content than their ...
132
Nilotinib A New FDA Approved Drug for the Treatment of Chronic Myelogenous Leukaemia
... 583.99(monohydrate) and 565.98(anhydrate). As it lacks chiral centre, therefore, no stereoisomers are possible. It appears as a white to slightly yellowish or slightly green-yellowish powder. It exists in three ...
7
Potential of ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia
... BCR-ABL tyrosine kinase inhibitors (TKIs) have improved outcomes for patients diagnosed with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic ...
8